Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ALNYLAM PHARMACEUTICALS, INC.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-88.6% vs price
Base Case (Median)
-80.7% vs price
Bull Case (75th pct.)
-61.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $24.37 | -89.0% | High (40%) |
| PE Comparable | $128.89 | -41.7% | Medium (25%) |
| Graham Number | $27.62 | -87.5% | Medium (40%) |
| EV/EBITDA | $57.64 | -73.9% | Medium (20%) |
| EV/FCF | $95.47 | -56.8% | Medium (20%) |
| Earnings Power Value | $10.75 | -95.1% | Medium (50%) |
Based on 6 out of 7 methods, ALNY appears overvalued at the current price of $220.98. The base case fair value of $42.63 implies 80.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.